Ariad Pharmaceuticals Inc | search
Click here to view Ariad Pharmaceuticals Inc news from 60+ newspapers.
Bookmark or Share- Japan’s Takeda to acquire US cancer drug manufacturer ARIAD for $5.2bnJapanese-based Takeda Pharmaceutical Company has signed an agreement to acquire American oncology company ARIAD Pharmaceuticals for approximately $5.2bn. With the acquisition of ARIAD, Takeda will gain access to the leukaemia drug Iclusig, as well as new lung cancer treatment drug Brigatinib.
- Takeda to Acquire ARIAD Pharmaceuticals, Inc.ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers.
- Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of its acquisition of ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) ("ARIAD") for $24.00 per share in cash.
- Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.Tender Offer Details. Takeda completed the acquisition through a tender offer and subsequent merger of ARIAD with Kiku Merger Co., Inc., a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. ARIAD is now an indirect wholly owned subsidiary of Takeda.
- Ariad Pharmaceuticals : Enters into Definitive Agreement to Be Acquired ...ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.
More
